3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
3
Breast Neoplasms
3
Weight Loss
2
Polyps
2
Hyperplasia
2
Stomach Neoplasms
1
Psoriasis
1
Osteoarthritis
1
Neoplasms
1
Muscular Atrophy
1
Muscle Weakness
1
Motor Activity
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Chronic-Phase
1
Colitis, Ulcerative
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Cancer Cachexia
1
Cachexia
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Anorexia
1
Adenomatous Polyps
1
Adenomatous Polyposis Coli
1
Interventions
Adalimumab
13
Methotrexate
11
Etanercept
10
Rituximab
5
Abatacept
5
tocilizumab
4
olokizumab
4
tofacitinib
3
golimumab
3
Infliximab
3
Tumor Necrosis Factor Inhibitors
2
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
Certolizumab Pegol
2
Antirheumatic Agents
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Arthritis, Rheumatoid
×
Eicosapentaenoic Acid
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts